Ilyas Sahin, M.D.
CLIN AST PROF
About Ilyas Sahin
Ilyas Sahin, MD, is an assistant professor with the division of hematology & oncology. At UF Health, he specializes in gastrointestinal oncology.
Dr. Sahin earned his medical degree from Hacettepe University Faculty of Medicine in Turkey. He then worked as postdoctoral research fellow in medical oncology at Dana-Farber Cancer Institute, Harvard Medical School.
He completed his internship at Montefiore Medical Center, Albert Einstein College of Medicine and a residency at Mount Auburn Hospital, Harvard Medical School, both in internal medicine. Most recently he completed a fellowship at Rhode Island Hospital, Brown University in hematology and oncology.
Before joining UF Health, Dr. Sahin was an assistant professor of medicine at The Warren Alpert Medical School, and a clinical hematologist/oncologist at Miriam Hospital with the Lifespan Cancer Institute.
Dr. Sahin’s research interests gave led to more than thirty research papers and abstracts. In addition to focusing on his own research which primarily focuses on cancer immunotherapy and immunotherapy resistance, he currently serves as Associate Editor for Frontiers in Oncology. His work on the role of MDM2 in immunotherapy resistance was published with multiple online news networks and it was among CDDpress journals monthly readers’ choice. Recently, he developed a novel preclinical animal model for hyperprogression, acceleration of cancer growth (more rapid than expected), which occurs in some of cancer patients receiving immunotherapy. This novel model may help understanding unusual patterns of response and/ or resistance to immunotherapies which may provide key knowledge to develop new therapies in cancer patients.
Dr. Sahin is board certified in Internal Medicine, Hematology and Medical Oncology. He is also a member of the American Society of Clinical Oncology.
Accomplishments
Pilot Project Award
2020
·
Cancer Center at Brown University
Board Certifications
-
HematologyAmerican Board Of Internal Medicine
-
Internal MedicineAmerican Board Of Internal Medicine
-
OncologyAmerican Board Of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
Areas of Interest
- Esophageal cancer
- Gastrointestinal cancer
- Liver cancer – hepatocellular carcinoma
- Stomach cancer
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-2070-9319
Publications
2023
Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
Cancers.
15(6)
[DOI] 10.3390/cancers15061808.
[PMID] 36980692.
2023
Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis
Journal of Hepatocellular Carcinoma.
Volume 10:1129-1141
[DOI] 10.2147/jhc.s417273.
2023
Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.
Oncotarget.
14:351-357
[DOI] 10.18632/oncotarget.28406.
[PMID] 37068159.
2023
Mechanisms of drug resistance in HCC.
Hepatology (Baltimore, Md.).
[DOI] 10.1097/HEP.0000000000000237.
[PMID] 36680397.
2023
The Role of HER2 Status in the Biliary Tract Cancers
Cancers.
15(9)
[DOI] 10.3390/cancers15092628.
[PMID] 37174094.
2023
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer.
The lancet. Gastroenterology & hepatology.
8(3)
[DOI] 10.1016/S2468-1253(22)00402-2.
[PMID] 36773612.
2023
Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
29(5):1206-1217
[DOI] 10.1177/10781552231171079.
[PMID] 37097888.
2022
Advanced Hepatocellular Carcinoma in Adults Without Cirrhosis: A Single-Institution Retrospective Review.
Journal of hepatocellular carcinoma.
9:1299-1307
[DOI] 10.2147/JHC.S384438.
[PMID] 36567797.
2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Future oncology (London, England).
[DOI] 10.2217/fon-2022-0392.
[PMID] 36399037.
2022
Nivolumab in Esophageal Squamous-Cell Carcinoma.
The New England journal of medicine.
386(20):1958-1959
[DOI] 10.1056/NEJMc2202880.
[PMID] 35584166.
2021
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Leukemia & lymphoma.
62(10):2457-2465
[DOI] 10.1080/10428194.2021.1919657.
[PMID] 33993837.
2021
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.
Scientific reports.
11(1)
[DOI] 10.1038/s41598-021-98760-9.
[PMID] 34588522.
2021
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
Blood Advances.
5(24):5525-5535
[DOI] 10.1182/bloodadvances.2021004512.
[PMID] 34551072.
2021
Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.
Oncotarget.
12(21):2131-2146
[DOI] 10.18632/oncotarget.28086.
[PMID] 34676046.
2021
Strategies to sensitize cancer cells to immunotherapy.
Human vaccines & immunotherapeutics.
1-7
[DOI] 10.1080/21645515.2021.1891817.
[PMID] 34019474.
2021
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
Frontiers in Oncology.
11
[DOI] 10.3389/fonc.2021.801379.
[PMID] 34956912.
2021
Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers
International Journal of Molecular Sciences.
22(21)
[DOI] 10.3390/ijms222111790.
[PMID] 34769221.
2020
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
Cell death discovery.
6
[DOI] 10.1038/s41420-020-0292-1.
[PMID] 32655895.
2020
Asciminib in Relapsed Chronic Myeloid Leukemia.
The New England journal of medicine.
382(14):1378-1379
[DOI] 10.1056/NEJMc2000116.
[PMID] 32242375.
2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection.
Oncotarget.
11(46):4201-4223
[DOI] 10.18632/oncotarget.27799.
[PMID] 33245731.
2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.08.02.230839.
[PMID] 32793908.
2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.
Blood advances.
3(7):995-1002
[DOI] 10.1182/bloodadvances.2018028456.
[PMID] 30940634.
2019
Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy.
British journal of haematology.
186(3):e31-e35
[DOI] 10.1111/bjh.15861.
[PMID] 30859554.
2019
Erythrophagocytosis on bone marrow found in severe autoimmune hemolytic anemia with reticulocytopenia.
Blood.
134(21)
[DOI] 10.1182/blood.2019002708.
2019
Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.
Cancer biology & therapy.
20(8):1047-1056
[DOI] 10.1080/15384047.2019.1595283.
[PMID] 30975030.
2019
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
OncoTargets and therapy.
12:1085-1094
[DOI] 10.2147/OTT.S165615.
[PMID] 30799938.
2019
Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy.
Integrative cancer therapies.
18
[DOI] 10.1177/1534735419835310.
[PMID] 30897972.
2018
Androgen receptor-independent prostate cancer: an emerging clinical entity.
Cancer biology & therapy.
19(5):347-348
[DOI] 10.1080/15384047.2018.1423926.
[PMID] 29333925.
2018
Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
The New England journal of medicine.
379(12)
[DOI] 10.1056/NEJMc1809507.
[PMID] 30260154.
2018
Refractoriness to red blood cell transfusion therapy due to hypersplenism.
Transfusion.
58(11):2513-2516
[DOI] 10.1111/trf.14876.
[PMID] 30260482.
2016
Drug Delivery Approaches for the Treatment of Cervical Cancer.
Pharmaceutics.
8(3)
[DOI] 10.3390/pharmaceutics8030023.
[PMID] 27447664.
2015
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
Cell reports.
12(4):622-35
[DOI] 10.1016/j.celrep.2015.06.059.
[PMID] 26190113.
2015
Early start of adjuvant chemotherapy in breast cancer.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
20(4)
[PMID] 26416072.
2014
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Blood.
123(26):4120-31
[DOI] 10.1182/blood-2014-03-564583.
[PMID] 24711662.
2014
CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.
Blood.
124(12):1905-14
[PMID] 25079359.
2014
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.
Blood cancer journal.
4
[DOI] 10.1038/bcj.2014.24.
[PMID] 24769645.
2014
Pyk2 promotes tumor progression in multiple myeloma.
Blood.
124(17):2675-86
[DOI] 10.1182/blood-2014-03-563981.
[PMID] 25217697.
2014
Role of endothelial progenitor cells in cancer progression.
Biochimica et biophysica acta.
1846(1):26-39
[DOI] 10.1016/j.bbcan.2014.03.005.
[PMID] 24709008.
2014
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
American journal of hematology.
89(11):1030-6
[DOI] 10.1002/ajh.23814.
[PMID] 25060991.
2014
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.
Blood.
124(11):1765-76
[DOI] 10.1182/blood-2014-03-560862.
[PMID] 25061176.
2014
Waldenström macroglobulinemia: from biology to treatment.
Expert review of hematology.
7(1):157-68
[DOI] 10.1586/17474086.2014.871494.
[PMID] 24405328.
2013
Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Medical oncology (Northwood, London, England).
30(3)
[DOI] 10.1007/s12032-013-0615-7.
[PMID] 23729267.
2013
The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression.
Leukemia.
27(4):961-4
[DOI] 10.1038/leu.2012.353.
[PMID] 23212153.
2011
Aspirin intake may prevent metastasis in patients with triple-negative breast cancer.
Medical oncology (Northwood, London, England).
28(4):1308-10
[DOI] 10.1007/s12032-010-9636-7.
[PMID] 20668965.
2011
Sequential taxane and anthracycline-containing neo-adjuvant regimens; any rationale behind the sequence?
Breast (Edinburgh, Scotland).
20(3)
[DOI] 10.1016/j.breast.2011.02.008.
[PMID] 21371886.
2010
How can Nolvadex abolish arthralgia in women taking newer generic Tamoxifen preparations?
Breast (Edinburgh, Scotland).
19(5)
[DOI] 10.1016/j.breast.2010.05.002.
[PMID] 20554203.
2010
Management of polyorchidism: Surgery or conservative management?
Journal of human reproductive sciences.
3(3):162-3
[DOI] 10.4103/0974-1208.74166.
[PMID] 21234184.
2010
Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
British journal of haematology.
151(5):530-1
[DOI] 10.1111/j.1365-2141.2010.08388.x.
[PMID] 20880117.
2010
Possible mechanisms behind taxane-anthracycline sequencing.
The Lancet. Oncology.
11(6):514-5
[DOI] 10.1016/S1470-2045(10)70067-X.
[PMID] 20522380.
Grants
Aug 2023
ACTIVE
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Role: Principal Investigator
Funding: CATALYST CLINICAL RESEARCH
via COMPASS THERAPEUTICS
May 2023
ACTIVE
Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 as a Single Agent and in Combination With Standard of Care in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I )
Role: Principal Investigator
Funding: PRECISION FOR MEDICINE
via OMEGA THERAPEUTICS
May 2023
ACTIVE
Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 as a Single Agent and in Combination With Standard of Care in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I )
Role: Principal Investigator
Funding: PRECISION FOR MEDICINE
via OMEGA THERAPEUTICS
Jan 2023
ACTIVE
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Dec 2022
ACTIVE
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Dec 2022
ACTIVE
Blood plasma and buffy coat samples including corresponding clinical information in de-identified form for each patient sample
Role: Co-Project Director/Principal Investigator
Funding: BILLIONTOONE
Sep 2022
ACTIVE
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Role: Principal Investigator
Funding: CLINIPACE INC
via SURFACE ONCOLOGY
Apr 2022
ACTIVE
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- i.sahin@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100278
GAINESVILLE FL 32610